Han ShouWei, Roman Jesse
Department of Medicine, Division of Pulmonary, Allergy & Critical Care Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Anticancer Drugs. 2007 Mar;18(3):237-44. doi: 10.1097/CAD.0b013e328011e67d.
Peroxisome proliferator-activated receptors are ligand-activated intracellular transcription factors that have been implicated in important biological processes such as inflammation, tissue remodeling and atherosclerosis. Emerging information also implicates peroxisome proliferator-activated receptors in oncogenesis. Peroxisome proliferator-activated receptor gamma, the best studied of the peroxisome proliferator-activated receptors, modulates the proliferation and apoptosis of many cancer cell types, and it is expressed in many human tumors including lung, breast, colon, prostate and bladder. Natural and synthetic agents capable of activating peroxisome proliferator-activated receptor gamma have been found to inhibit cancer cell growth in vitro and in animal models. These agents, however, are not specific and both peroxisome proliferator-activated receptor gamma-dependent and peroxisome proliferator-activated receptor gamma-independent pathways involved in their effects have been identified. Together, these studies, coupled with a few clinical trials, suggest that peroxisome proliferator-activated receptor gamma is a novel target for the development of new and effective anticancer therapies.
过氧化物酶体增殖物激活受体是配体激活的细胞内转录因子，参与炎症、组织重塑和动脉粥样硬化等重要生物学过程。新出现的信息还表明过氧化物酶体增殖物激活受体与肿瘤发生有关。过氧化物酶体增殖物激活受体γ是研究最深入的过氧化物酶体增殖物激活受体，可调节多种癌细胞类型的增殖和凋亡，在包括肺癌、乳腺癌、结肠癌、前列腺癌和膀胱癌在内的许多人类肿瘤中均有表达。已发现能够激活过氧化物酶体增殖物激活受体γ的天然和合成药物在体外和动物模型中均可抑制癌细胞生长。然而，这些药物并不具有特异性，且已确定其作用涉及过氧化物酶体增殖物激活受体γ依赖性和非依赖性途径。这些研究与一些临床试验共同表明，过氧化物酶体增殖物激活受体γ是开发新型有效抗癌疗法的新靶点。
